2017 Fiscal Year Final Research Report
Development of novel treatments of myeloma based on MRD using next-generation sequencing and protein-array assay
| Project/Area Number |
15K08644
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Laboratory medicine
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
NISHIKAWA Hiroyoshi 国立がん研究センター, 先端医療開センター, 免疫TR分野長 (10444431)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | 多発性骨髄腫 / 微小残存病変 / 癌精巣抗原 |
|---|
| Outline of Final Research Achievements |
We demonstrated the clinical value of minimal residual disease (MRD) detection in multiple myeloma (MM) patients using next-generation sequencing (NGS) and multiparameter flow cytometry (MFC). When MRD negativity in bone marrow and/or autografts of MM patients was achieved, the progression-free survival and overall survival were dramatically improved. Based on the results, we have started the clinical study "Prognostic value of minimal residual disease detection using multiparameter flow cytometry (EuroFlow method) in patients with multiple myeloma who underwent autologous stem cell transplantation: comparison with sequencing-based method (UMIN-CTR ID: UMIN000022238)". On the other hand, we clarified that anti-X antibody which is detected in the sera of MRD negative MM patients binds to a cancer-testis antigen X.
|
| Free Research Field |
多発性骨髄腫および関連疾患
|
